Victory Capital Management Inc Alnylam Pharmaceuticals, Inc. Transaction History

Victory Capital Management Inc

  • $99 Billion
  • Q3 2024

A detailed history of Victory Capital Management Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 42,909 shares of ALNY stock, worth $11.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
42,909
Previous 38,680 10.93%
Holding current value
$11.4 Million
Previous $9.4 Million 25.58%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024
BUY
$233.81 - $287.01 $988,782 - $1.21 Million
4,229 Added 10.93%
42,909 $11.8 Million
Q2 2024

Aug 05, 2024
SELL
$143.31 - $247.0 $103,756 - $178,828
-724 Reduced 1.84%
38,680 $9.4 Million
Q1 2024

May 03, 2024
SELL
$146.51 - $198.2 $927,994 - $1.26 Million
-6,334 Reduced 13.85%
39,404 $5.89 Million
Q4 2023

Feb 05, 2024
SELL
$151.41 - $196.57 $1.99 Million - $2.58 Million
-13,149 Reduced 22.33%
45,738 $8.75 Million
Q3 2023

Nov 06, 2023
SELL
$170.77 - $211.65 $274,256 - $339,909
-1,606 Reduced 2.65%
58,887 $10.4 Million
Q2 2023

Jul 27, 2023
SELL
$185.01 - $212.05 $69,748 - $79,942
-377 Reduced 0.62%
60,493 $11.5 Million
Q1 2023

May 02, 2023
BUY
$182.66 - $235.53 $134,803 - $173,821
738 Added 1.23%
60,870 $12.2 Million
Q4 2022

Feb 10, 2023
SELL
$185.53 - $241.31 $69,573 - $90,491
-375 Reduced 0.62%
60,132 $14.3 Million
Q4 2022

Feb 09, 2023
BUY
$185.53 - $241.31 $263,452 - $342,660
1,420 Added 2.4%
60,507 $14.4 Million
Q3 2022

Nov 02, 2022
BUY
$138.54 - $232.0 $1.08 Million - $1.81 Million
7,822 Added 15.26%
59,087 $11.8 Million
Q2 2022

Aug 01, 2022
SELL
$120.42 - $169.29 $26,492 - $37,243
-220 Reduced 0.43%
51,265 $7.48 Million
Q1 2022

May 04, 2022
SELL
$127.18 - $173.91 $620,256 - $848,159
-4,877 Reduced 8.65%
51,485 $6.87 Million
Q4 2021

Feb 07, 2022
BUY
$159.56 - $209.29 $77,227 - $101,296
484 Added 0.87%
56,362 $9.56 Million
Q3 2021

Nov 02, 2021
BUY
$169.75 - $207.73 $2.5 Million - $3.07 Million
14,756 Added 35.88%
55,878 $10.6 Million
Q2 2021

Aug 03, 2021
SELL
$128.63 - $176.89 $2.18 Million - $2.99 Million
-16,922 Reduced 29.15%
41,122 $6.97 Million
Q1 2021

May 04, 2021
BUY
$126.83 - $175.69 $897,956 - $1.24 Million
7,080 Added 13.89%
58,044 $8.2 Million
Q4 2020

Feb 01, 2021
BUY
$122.97 - $147.0 $756,388 - $904,197
6,151 Added 13.73%
50,964 $6.62 Million
Q3 2020

Nov 09, 2020
BUY
$121.19 - $165.49 $815,123 - $1.11 Million
6,726 Added 17.66%
44,813 $6.53 Million
Q2 2020

Aug 07, 2020
SELL
$104.21 - $156.44 $305,335 - $458,369
-2,930 Reduced 7.14%
38,087 $5.64 Million
Q1 2020

May 04, 2020
BUY
$93.12 - $133.99 $2.29 Million - $3.29 Million
24,544 Added 149.0%
41,017 $4.47 Million
Q4 2019

Feb 06, 2020
BUY
$74.51 - $124.23 $152,894 - $254,919
2,052 Added 14.23%
16,473 $1.9 Million
Q4 2019

Feb 04, 2020
SELL
$74.51 - $124.23 $68,921 - $114,912
-925 Reduced 6.03%
14,421 $1.66 Million
Q3 2019

Nov 12, 2019
BUY
$70.9 - $87.82 $1.09 Million - $1.35 Million
15,346 New
15,346 $1.23 Million
Q2 2018

Aug 02, 2018
SELL
$88.31 - $107.8 $1.37 Million - $1.68 Million
-15,555 Closed
0 $0
Q1 2018

May 04, 2018
SELL
$115.92 - $148.54 $507,729 - $650,605
-4,380 Reduced 21.97%
15,555 $1.85 Million
Q4 2017

Feb 01, 2018
SELL
$114.49 - $139.98 $370,947 - $453,535
-3,240 Reduced 13.98%
19,935 $2.53 Million
Q3 2017

Oct 27, 2017
SELL
$72.53 - $118.27 $206,710 - $337,069
-2,850 Reduced 10.95%
23,175 $2.72 Million
Q2 2017

Aug 07, 2017
BUY
N/A
26,025
26,025 $2.08 Million

Others Institutions Holding ALNY

# of Institutions
645
Shares Held
109M
Call Options Held
1.28M
Put Options Held
1.22M
View Full List

About ALNYLAM PHARMACEUTICALS, INC.

ALNY Quotes by TradingView
  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $32.8B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email